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a  b  s  t  r  a  c  t
Maternal  serum  cortisol  has  been  suggested  to be inﬂuenced  by  psychiatric  morbidity,  and  may  also  inﬂu-
ence  fetal  growth.  However,  several  studies  found  equal  cortisol  levels  in  depressed  and  healthy  pregnant
women. Placental  11--hydroxysteroid  dehydrogenase  type  2 (11-HSD2)  shields  the  fetus  from  mater-
nal  cortisol  by conversion  to cortisone,  a function  that may  be  compromised  by  maternal  stress.  We  aimed
to compare  the  serum  ratio  of cortisone  to cortisol,  in  women  with  and  without  psychiatric  morbidity
during  pregnancy.  A  secondary  aim  was  to  investigate  whether  fetal  growth,  approximated  by  infant
birth  weight,  was associated  with  the  cortisone  to cortisol  ratio.
We performed  tandem  mass  spectrometry  analysis  of  serum  cortisol  and  cortisone  in  late  pregnancy
in  94  women  with  antenatal  psychiatric  morbidity  and  122  controls  (cohort  1).  We  also  compared  the
placental  gene  expression  of  HSD11B1  and  2 in  another  group  of  69  women  with  psychiatric  morbidity
and  47 controls  (cohort  2).
There  were  no  group  differences  in cortisol  to cortisone  ratio,  absolute  levels  of cortisone  and  cortisol
(cohort  1),  or  expression  of  HSD11B1  or 2  (cohort  2). However,  cortisone  to cortisol  ratio  was  positively
associated  with  birth  weight  in  women  with  psychiatric  morbidity,  also  after  adjustment  for  gestational
length,  fetal sex,  maternal  height,  smoking,  SSRI  use,  and  time  of  blood  sampling  (standardized    = 0.35,
p <  0.001),  with  no association  in the  healthy  controls
Thus,  the  maternal  serum  cortisone  to cortisol  ratio  does  not  seem  to be  affected  by psychiatric  morbid-
ity, but  psychiatric  morbidity  may  increase  fetal exposure  to cortisol  or other  metabolic  factors  inﬂuencing
fetal  growth.
© 2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Cortisol metabolism during pregnancy affects the neuroen-
ocrinology of the pregnant woman as well as her fetus. Cortisol is
ssential for fetal organ maturation (de Fencl and Tulchinsky, 1975;
og-Zielinska et al., 2013), but excess cortisol exposure can impair
etal growth (Edwards et al., 1993; Stewart et al., 1995), and may
ave programming effects on the child’s hypothalamic-pituitary-
∗ Corresponding author.
E-mail address: charlotte.hellgren@kbh.uu.se (C. Hellgren).
ttp://dx.doi.org/10.1016/j.psyneuen.2016.04.006
306-4530/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
adrenal-(HPA) axis reactivity (Alexander et al., 2012; Davis et al.,
2011). Maternal serum cortisol concentrations increase over the
course of pregnancy (Jung et al., 2011), but the placenta shields
the fetus from excess cortisol by expressing 11--hydroxysteroid
dehydrogenase type 2 (11-HSD2), an enzyme that converts cor-
tisol into inactive cortisone (Murphy et al., 1974). Its isozyme
11-HSD1, predominantly converts cortisone to cortisol (Ricketts
et al., 1998).
The increased cortisol and corticotropin releasing hormone
(CRH) levels often seen in depressed patients has been implicated as
a mediator of the association between depression during pregnancy
and lower birth weight, as well as shorter gestational length (Field
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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t al., 2006; Hannerfors et al., 2015; Sandman et al., 2006). How-
ver, a number of studies show similar levels of cortisol in blood,
aliva, and urine of women suffering from depression or anxiety
uring pregnancy compared to healthy controls (Hellgren et al.,
013; see Iliadis et al., 2015 for a review). Certainly, fetal cortisol
xposure is affected by other factors than maternal cortisol pro-
uction. It is known that severe stress, such as undernutrition, can
ecrease placental 11-HSD2 activity in rodents (Langley-Evans
t al., 1996) and, more recently, lower placental 11-HSD2 expres-
ion and activity has been found in women with higher levels of
nxiety or depression (O’Donnell et al., 2012). Thus, fetal corti-
ol exposure may  be increased when the mother is suffering from
sychiatric morbidity, even when her own serum cortisol is not
arkedly different from that of healthy pregnant women.
Since the placenta clears some of the maternal cortisol, the
aternal serum cortisone to cortisol ratio is likely to reﬂect mater-
al and placental 11-HSD2 activity and may  therefore be a better
ndicator than solely cortisol of the magnitude by which the mater-
al cortisol levels inﬂuence the fetus. Placental 11-HSD2 activity
s inﬂuence by a multitude of factors. Based on the suggestion that
aternal mood has an effect (O’Donnell et al., 2012), we hypoth-
sized that this would be detected as a decrease in the maternal
ortisone to cortisol ratio in women with psychiatric symptoms
uring pregnancy. There are not many published reports of serum
ortisone concentrations in pregnant women, and more impor-
antly, none have used tandem mass spectrometry, a method which
as been shown to be superior for determination of cortisol levels
n late pregnancy (Jung et al., 2011).
The aim of this study was to test the hypothesis that serum cor-
isone to cortisol ratio during late pregnancy is lower in women
ith antenatal psychiatric morbidity compared to healthy controls.
econdary aims were to explore whether the cortisone to corti-
ol ratio was associated with birth weight and/or gestational age
t delivery, and to determine if the ratio interacted with maternal
sychiatric morbidity in inﬂuencing birth weight and/or gestational
ength. Lastly, we wanted to test the hypothesis that placental gene
xpression of HSD11B1 and 2 is lower in women with psychiatric
orbidity compared to controls.
. Methods
.1. Setting
Pregnant women were recruited within the ‘Biology, Affect,
tress, Imaging, and Cognition in pregnancy and the puerperium’
BASIC) cohort. The BASIC study investigates biological correlates of
ood and anxiety disorders during pregnancy and in the postpar-
um period. A majority of all pregnant women in Uppsala County,
weden are invited to participate around their routine ultrasound
xamination in gestational week 17. Exclusion criteria for the BASIC
tudy are (1) inability to adequately communicate in Swedish, (2)
onﬁdentially kept personal data, (3) ultrasound ﬁndings lead-
ng to termination of pregnancy, and (4) age under 18 years. The
omen who participate (around 23% of the county births) ﬁll out
eb-based questionnaires, including the Swedish version of the
dinburgh Postnatal Depression Scale (EPDS) (Cox et al., 1987;
ickberg and Hwang, 1996) in gestational weeks 17 and 32. A
ajority of the participating women also consent to the collection
f placental biopsies. The study procedures are in accordance with
thical standards for human experimentation and the study was
pproved by the Regional Ethical Review Board in Uppsala.The study is based on two cohorts within the BASIC project.
ohort 1 is composed of women who have attended a late preg-
ancy visit to our laboratory, including serum sampling and a
sychiatric interview (see Section 2.2.1). Cohort 2 contains acrinology 69 (2016) 142–149 143
selection of the participants from whom placental samples were
available (see Section 2.2.2).
2.2. Participants and procedure
2.2.1. Primary study population, cortisone to cortisol ratio
(cohort 1)
For the current study, we invited BASIC participants with EPDS
score ≥13 in gestational week 32, and a random sample of women
with EPDS scores <13 at gestational week 32, with the inten-
tion of oversampling women  with antenatal depressive symptoms
(Rubertsson et al., 2011). The participants visited the research
laboratory at the Department of Women’s and Children’s Health,
Uppsala University in gestational week 35–39 (according to the
ultrasound-estimated date of delivery) between January 2010 and
May  2013. The visits were scheduled between 8 AM and 3 PM,  with
the majority starting either at 9 AM or at 1 PM.
After providing written informed consent, the women were
interviewed about ongoing depressive and primary anxiety dis-
orders with the Swedish version of the Mini International
Neuropsychiatric Interview (MINI), a structured interview based
on DSM-IV criteria (Sheehan et al., 1998). The interview also
included questions on previous depressive episodes. All partici-
pating women  were interviewed about use of medication in the
preceding three months and ﬁlled out the EPDS and the trait version
of the State-Trait Anxiety Inventory (STAI-T) (Spielberger, 1983)
during the visit. At the end of the 90 min  visit, a venous blood
sample was  drawn.
In addition, EPDS scores from gestational weeks 17 and 32,
medications taken during pregnancy, and educational level, were
available from the web questionnaires. Data on smoking during
the ﬁrst trimester, obstetric complications, mean arterial pressure
at the last visit to midwife during pregnancy, date of delivery,
and infant sex, weight, and length was  obtained from the medical
records.
Out of a total 234 participating women, serum samples were
available from 216 women. Ninety-four of these women were clas-
siﬁed as suffering from psychiatric morbidity during pregnancy.
Women  with an ongoing minor (two to four symptoms persisting
for at least two weeks) or an ongoing major depressive episode (at
least ﬁve symptoms persisting for at least two  weeks), or a prior
episode in combination with at least one EPDS score of 13 or more
during pregnancy, were considered to have experienced a depres-
sive episode during pregnancy (n = 59) (with or without psychiatric
comorbidities). The remaining women  in the psychiatric morbidity
group had either a current anxiety disorder (n = 9), an ongoing eat-
ing disorder (n = 2), at least one EPDS score ≥13 during pregnancy
(n = 14), and/or ongoing treatment with antidepressants (n = 10).
Women  with no ongoing depressive or anxiety disorder accord-
ing to the MINI interview, no ongoing psychotropic treatment, and
EPDS scores <13 in gestational week 17 and 32, and at the visit,
were considered as healthy controls (n = 122).
2.2.2. Placental gene expression population (cohort 2)
As part of the BASIC study, postpartum placental biopsies were
collected for placental gene expression analyses. From a total of
931 placental biopsies, all singleton placentas where the mother
was affected by psychiatric morbidity during pregnancy (n = 69), as
indicated by SSRI use (n = 44), or non-medicated psychiatric mor-
bidity during pregnancy, according to medical records (or ongoing
MINI-diagnosis when available) (n = 25), plus a random selection of
healthy controls (n = 47), were selected for placental gene expres-
sion analysis. Cohort 2 was only partly overlapping (n = 33) with
cohort 1. Group characteristics are found in Supplementary Table
1.
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Fig. 1. Scatterplot showing the relationship between the natural logarithm trans-
formed maternal serum cortisone to cortisol ratio and fetal birth weight. The
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aotted line represents the linear regression of the healthy controls (, standard-
zed   = −0.001, p = 0.991), and the solid line the linear regression of the women
ith psychiatric morbidity during pregnancy (©, standardized  = 0.371, p < 0.001).
.3. Tandem mass spectrometry determination of total serum
ortisol and cortisone (cohort 1)
.3.1. Sample preparation
A slightly modiﬁed method of steroid extraction was used (Liu
t al., 2011). 200 L of serum was mixed with the internal standard
ixture. The internal standard mixture was prepared with d4 cor-
isol in methanol. After the addition of internal standard to serum
amples, each contain 2.5 ng of d4 cortisol. Extraction of steroids
rom human serum was done using 2 mL  of tertbutylmethyl ether
MTBE) as the extraction solvent. Samples were gently vortexed
or 10 min  and centrifuged at 1000 g for 10 min. The supernatant
as collected and the solvent was evaporated under a stream of
itrogen gas. The dried samples were reconstituted with 80 L
ethanol. During the extraction, the lipids were protected against
xidation by the addition of 0.05 mg/mL  butylated hydroxytoluene
BHT) to the extraction solvent (MTBE).
.3.2. Separation of steroids by ultra performance convergence
hromatography (UPC2)
The Acquity UPC2 system from Waters Corporation, Milford,
SA, was equipped with a binary solvent delivery pump, an
utosampler, a column oven and a back pressure regulator. The
ualitative analysis was performed at 40 ◦C using an Acquity UPC2
EH column (100 mm 3.0 mm,  1.7 m;  Waters, Milford, MA, USA).
he mobile phase ﬂow rate was maintained at 3.0 mL/min with a
radient elution (eluent A, CO2; eluent B, methanol). The gradient
rogram was started with 2% of component B, then, a linear gra-
ient was programmed from 2% to 17% for 2.0 min, followed by a
inear gradient down to 2% B in 3.0 min, and ﬁnally it was  held for
.0 min  which allowed ionic liquids to elute out from the instru-
ent. Isocratic solvent was methanol in 0.1% formic acid with a
ow rate of 0.4 mL/min. The back pressure was set at 1800 psi and
he injection volume was 2.0 L.
.3.3. Identiﬁcation of serum cortisol and cortisone by tandem
ass spectrometry (Xevo TQ-S)
Steroids were identiﬁed by using a Waters Xevo TQ-S mass
pectrometer (Milford, MA,  USA). The data acquisition was  in the
ositive ion electrospray ionization (ESI) mode. The desolvation
as was nitrogen, and the collision gas was argon (0.25 mL/min).
he data acquisition range was m/z 50–800. The capillary volt-
ge was 2.0 kV, the cone voltage was 30.0 V, and the source offsetcrinology 69 (2016) 142–149
was 20 V. The source temperature was 150 ◦C and the desolva-
tion temperature was 500 ◦C with the desolvation gas ﬂow rate
of 750.0 L/h. The cone gas ﬂow was  150.0 L/h. The nebulizer gas
ﬂow at 7.0 bar. MS  data were collected using two  separate scan
functions. The ﬁrst scan function was set at low collision energy
(5 eV), which provided parent ions, and the second scan function
was set a high collision energy (ramped from 15 to 30 eV). The scan
time for each function was set at 0.3 s. The MS  data acquired in the
m/z range of 100–1200. The precursor/product ion transitions in
multiple reactions monitoring (MRM)  were used for mass analysis
and quantiﬁcation. The pertinent mass transitions of cortisol, corti-
sone and internal standard were 363.05/121.2, 327.2; 361.5/163.0
and 367.25/121.0, respectively. The quantiﬁcation of analytes was
accomplished using internal standard and the retention time of the
analytes were also compared against standard steroids for peak
identiﬁcation. Moreover, relevant mass transitions were compared
with mass transitions obtained from standard steroids. The sample
analysis was  performed in triplicate. The values of relative standard
deviation (RSD) of intra-day repeatability were 2.53 for cortisol
and 4.07 for cortisone. The RSD values for inter-day repeatability
were 1.07 and 3.78 for cortisol and cortisone, respectively. All data
collected in centroid mode were obtained using MasslynxNT4.1
software (Waters Corp., Milford, MA USA).
2.4. Placental expression of HSD11B1 and 2 (cohort 2)
Placental tissue was  sampled postpartum, by the midwife’s
assistants attending the deliveries. Two  basal plate biopsy speci-
mens of the maternal–fetal interface, approximately 2 cm in size,
were excised from the central part of the placenta in a way that
each sample contained the decidua basalis and villous placenta.
Areas involving calciﬁcation or infarcts were avoided. The biop-
sies were rinsed in sterile phosphate-buffered saline, frozen on
dry ice within 30 min  after the delivery, and stored at −70 ◦C
until preparation for mRNA level analysis. Total RNA from pla-
cental tissue from the fetal side was isolated with a commercial
kit (#74106, Qiagen, Hilden, Germany). The ﬁrst-strand cDNA was
prepared from 250 ng of total RNA with Superscript VILO (Life Tech-
nologies, Paisley, UK) following the manufacturer’s protocol. For
real-time PCR, 100 ng of cDNA was analyzed with custom TaqMan
low-density array cards (Applied Biosystems, Carlsbad, CA) cover-
ing 48 genes encoding proteins related to monoaminergic signaling,
nerve growth factor signaling, and HSD11B1 (Hs00194153 m1)  and
HSD11B2 (Hs00930759 g1) (ABI Prism 7900HT Sequence Detection
System, ABI Prism 7900HT SDS Software 2.4, Applied Biosystems).
Eight samples were randomly analyzed per card in one run. Ther-
mal  cycling conditions were 2 min  at 50 ◦C and 10 min at 95 ◦C,
followed by 40 cycles of 15 s at 95 ◦C and 1 min  at 60 ◦C. Four
reference genes (ACTB, Hs01060665 g1; TOP1, Hs00243257 m1;
YWHAZ, Hs03044281 g1; GAPDH,  Hs99999905 m1)  were initially
analyzed. Using NormFinder (Andersen et al., 2004), YWHAZ  and
GAPDH were chosen as reference genes based on low intra- and
intergroup variation. The relative expression (CT) was thus cal-
culated as the number of cycles to detection threshold (CT) for the
target gene minus the CT for YWHAZ, Hs03044281 g1 and GAPDH
(Hs99999905 m1).
2.5. Statistical analyses
A sample size estimation based on previously published corti-
sone levels in late pregnancy (Seron-Ferre et al., 2001) suggested
that equal group sizes of 87 women  would render a statistical
power of 0.8 at an alpha level of 0.05 to detect a group difference
of ten percent.
Owing to the scarcity of previous publications on maternal
serum cortisone, we  performed bivariate correlations, and cate-
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orical comparisons, of cortisol, cortisone and their ratio against
 list of available possible confounders. The inclusion of covariates
n the ﬁnal model was based on previous ﬁndings in the literature
Goedhart et al., 2010), and signiﬁcant associations in the bivariate
nalyses.
The absolute values of cortisol, cortisone, and the cortisone to
ortisol ratio were found not to be normally distributed (Shapiro-
ilk = 0.771, 0.692, and 0.744) respectively. The cortisone to
ortisol ratio approached, but did not reach, normal distribu-
ion after natural logarithm transformation (Shapiro-Wilk = 0.896).
ence, the non-parametric Spearman’s rho (rs) was  calculated for
ivariate correlations and Mann-Whitney U-tests were used for
roup comparisons of the cortisone to cortisol ratio, using non-
ransformed values. The natural logarithm transformed ratio was
sed in the ANOVA and regression models, and the unstandardized
esiduals from the regression were checked for normality.
To investigate a possible interaction between cortisone to cor-
isol ratio and group (healthy controls vs. psychiatric morbidity),
 univariate ANOVA was performed with infant birth weight as
he dependent variable and cortisone to cortisol ratio, group, and
 term for the interaction between cortisone to cortisol ratio and
roup as independent factors. To follow up the results from the
NOVA, a linear regression analysis, stratiﬁed for group, was per-
ormed. This model was adjusted for known confounders, including
actors known to inﬂuence birth weight (maternal height (cm),
arity (primi-/multiparous), infant sex, gestational age at deliv-
ry (days), smoking during the ﬁrst trimester, and antidepressant
se), or known to inﬂuence cortisol and cortisone concentrations
gestational age at sampling (days), hour of day at sampling).
For cohort 2, assuming the mean and standard deviation of rela-
ive HSD11B2 mRNA observed by Murphy and Clifton, 2003, group
izes of 51 women gave a power of 0.8 to detect a group differ-
nce of 30% (the approximate difference seen between high and
ow anxiety scorers in O’Donnell et al. (2012)).
The Ct-values of HSD11B1, but not HSD11B2, were normally
istributed; analyses were made with Mann-Whitney U-tests and
on-parametric correlations.
P-values below 0.05 were considered signiﬁcant and all analyses
ere performed with the IBM SPSS 20 software. Unless otherwise
peciﬁed, data is presented as mean ± standard deviation for nor-
ally distributed variables (as approximated by a Shapiro-Wilk
tatistic >0.95), and as median with interquartile range for non-
ormally distributed data (Shapiro-Wilk statistic <0.95).
. Results
.1. Participant characteristics (cohort 1)
All participating women  had singleton pregnancies ending in
ive births. The vast majority of participants (n = 215, 99.5%) were
f Caucasian ethnicity, and were married or cohabiting (n = 214,
9.1%). Table 1 shows the group characteristics of healthy con-
rols and the women with psychiatric morbidity during pregnancy.
tudy participant characteristics in relation to cortisol, cortisone,
nd the cortisone to cortisol ratio, are shown in Table 2 (contin-
ous variables) and Table 3 (categorical variables). Women  with
sychiatric morbidity were on average younger and less likely to
ave a higher education. Their gestational age was on average two
ays shorter on the day of blood sampling, but there were no group
ifferences in gestational age at delivery or birth weight..2. Cortisone to cortisol ratio distribution (cohort 1)
The cortisone to cortisol ratio displayed a bimodal distribution,
ith one larger population with a normally distributed ratio undercrinology 69 (2016) 142–149 145
1 (n = 168, Shapiro-Wilk = 0.985), and a smaller population with a
normally distributed ratio above 1 (n = 48, Shapiro-Wilk = 0.980)
(Fig. 1). None of our recorded demographic variables distinguished
between the two populations (Supplementary Table 2).
3.3. Group differences in cortisol metabolism variables (cohort 1)
There were no signiﬁcant differences in serum cortisone to cor-
tisol ratio, or absolute values between women with psychiatric
morbidity and healthy controls (Table 1). Similarly, no differences
in serum cortisol, cortisone, or cortisone to cortisol ratio were found
between healthy controls and women with a depressive episode
during pregnancy (n = 59), or women  with an ongoing anxiety dis-
order (n = 30), both p-values = 0.6 (Mann-Whitney U-tests).
3.4. Cortisol metabolism variables in relation to gestational
length and birth weight (cohort 1)
Bivariate analyses in the entire study population showed that
the cortisone to cortisol ratio was in a weak but signiﬁcant correla-
tion with birth weight while neither the gestational length nor the
infants’ birth length was  associated with the cortisone to cortisol
ratio (Table 2). The absolute level of cortisone was in borderline
signiﬁcant positive correlation with infant birth weight (rs = 0.134,
p = 0.050), while cortisol was not (rs = 0.050, p = 0.5). Neither cor-
tisol nor cortisone was correlated with gestational age at delivery
(rs = 0.022, p = 0.8 and rs = −0.008, p = 1.0, respectively).
The ANOVA revealed a signiﬁcant interaction between group
and cortisone to cortisol ratio on birth weight (F(1, 212) = 9.2,
p = 0.003). Follow-up stratiﬁed regression analyses indicated that
the interaction was  driven by the psychiatric morbidity group in
which the cortisone to cortisol ratio was positively associated with
lower birth weight (=0.35, p < 0.001), after adjustment for mater-
nal height, parity, infant sex, gestational age at delivery, smoking,
SSRI use, gestational age at sampling, and hour of day at sam-
pling (Table 4). In contrast, no association between the cortisone
to cortisol ratio and birth weight was  noted among the healthy
controls (=0.06, p = 0.368). The unstandardized residuals from the
stratiﬁed regression model were normally distributed (Shapiro-
Wilk = 0.984, and 0.987 for the healthy controls and the psychiatric
morbidity group respectively). The unadjusted regression models
are displayed in Fig. 1
3.5. . HSD11B1and 2 placental gene expression (cohort 2)
Placental HSD11B1 or 2 gene expression did not differ between
women with psychiatric morbidity and healthy controls (Supple-
mentary Table 2). Placental CT-values of HSD11B1 correlated
negatively with birth weight (rs = −0.229, p = 0.013), while HSD11B2
CT-values correlated positively (rs = 0.200, p = 0.032, n = 116),
indicating higher expression of HSD11B1 with higher birth weight,
and lower birth weight with higher expression of HSD11B2. The
CT-values of HSD11B2, but not 1, was  correlated with gesta-
tional length (HSD11B1: rs = −0.160, p = 0.088; HSD11B2: rs = 0.242,
p = 0.009, n = 115).
In women  who  were part of both cohorts, cortisone serum
concentrations were in signiﬁcant correlation with the placen-
tal HSD11B2 mRNA CT-values (rs = 0.397, p = 0.022, n = 33, i.e. in
negative correlation with relative gene expression). No other cor-
relations between the placental gene expression and maternal
cortisol, cortisone, or cortisone to cortisol ratio were noted (all
p-values > 0.3).
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Table 1
Characteristics of healthy controls and women with psychiatric morbidity during pregnancy (cohort 1). Data displayed as mean (±SD), n (%), or median (IQR).
Healthy controls (n = 122) Psychiatric morbidity (n = 94) pa
Demographic
Age, years 32.2 ± 4.1 30.1 ± 4.7 0.001
Education >12 years 105 (86.8%) 68 (73.9%) 0.017
Primipara 51 (41.8%) 47 (50.0%) 0.3
First  trimester BMI, kg/m2 23.2 (21.5–26.2) 23.8 (21.3–26.6) 0.6
Smoking during 1st trimester 2 (1.6%) 6 (6.4%) 0.1
AM  blood sampling 65 (53.3%) 54 (57.4%) 0.6
Gestational age at sampling, days 264 ± 5 262 ± 7 0.007
Gestational age at delivery, days 282 ± 7 282 ± 8 0.8
Infant  birth weight, g 3721 ± 460 3700 ± 483 0.8
Psychiatric morbidity
EPDS score gestational week 17 5 (2–8) 11 (7–15) >0.001
EPDS  score gestational week 32 5 (2.75–8.25) 14 (10–16) >0.001
EPDS  score at visit 3 (1–5) 8 (5–12) >0.001
STAI-T  score at visit 32.3 ± 7.6 43.6 ± 9.9 >0.001
SSRI  treatment at visit 0 20 (21.3%) >0.001
Other  psychotropic medication 0 1 (1.1%) n.c.
Depressive episode during pregnancy 0 59 (62.8%) >0.001
Anxiety disorder during pregnancy 0 30 (31.9%) >0.001
Eating  disorder during pregnancy 0 2 (2.1%) n.c.
Serum concentrations
Cortisol, nmol/L 159 (111–231) 174 (121–251) 0.4
Cortisone, nmol/L 88.0 (64.0–225) 86.7 (65.2–121) 1.0
Cortisone to cortisol ratio 0.54 (0.40–1.11) 0.56 (0.39–0.76) 0.8
N.c.: not calculated, Valid percentages are reported in cases of missing data.
a According to independent t-tests, Mann-Whitney U test, Pearson 2, or Fisher’s exact test.
Table 2
Characteristics of participating mothers (cohort 1) along with each continuous variable’s non-parametric correlation coefﬁcients (Spearman’s rho, rs) with maternal serum
cortisol, cortisone, and cortisone to cortisol ratio.
Variable (n) Serum cortisol (rs) Serum cortisone (rs) Cortisone to cortisol ratio (rs)
Age, years (216) −0.01 −0.04 −0.03
Height, cm (216) 0.04 0.04 0.04
First trimester BMI, kg/m2 (210) −0.01 −0.01 −0.02
Gestational age at sampling, days (216) −0.02 −0.05 −0.04
Days until parturition at sampling (216) 0.04 0.05 0.06
Gestational age at delivery, days (216) 0.02 −0.01 0.02
Infant birth weight, g (213) 0.05 0.13a 0.15b
Infant birth length, cm (208) 0.07 0.12c 0.08
Mean arterial blood pressure, mmHg  (215) 0.00 0.07 0.06
ap = 0.050.
bp = 0.032.
cp = 0.076.
All other p-values > 0.1.
Table 3
Maternal cortisol, cortisone, and their ratio, in relation to potential confounders (cohort 1).
n (%) Serum cortisol nmol/L median (IQR) Serum cortisone nmol/L median (IQR) Cortisone to cortisol ratio median (IQR)
All 216 163 (119–240) 87.7 (64.4–158) 0.55 (0.39–0.82)
Infant  sex
Female 96 (45.1%) 157 (119–231) 87.8 (63.1–163) 0.55 (0.41–0.77)
Male  117 (54.9%) 166 (118–248) 87.7 (65.1–179) 0.56 (0.40–0.85)
Parity
Primipara 98 (45.4%) 151 (121–236) 90.7 (67.1–194) 0.58 (0.41–0.88)
Multipara 118 (54.6%) 173 (115–241) 86.7 (62.3–143) 0.53 (0.37–0.76)
Education
≤12  years 40 (18.8%) 155 (118–213) 84.0 (63.6–114) 0.54 (0.40–0.75)
>12  years 173 (81.2%) 163 (118–244) 87.7 (64.4–196) 0.56 (0.40–0.85)
Blood  sampling time
9–12 AM 119 (55.1%) 177 (118–251) 89.3 (65.3–158) 0.57 (0.38–0.83)
12.30–16 PM 97 (44.9%) 152 (119–205) 86.1 (62.7–172) 0.54 (0.41–0.77)
SSRI  treatment at visit 20 (9.3%) 135 (115–213) 90.0 (66.0–109) 0.60 (0.49–0.72)
Smoking during 1st trimester 8 (3.7%) 172 (128–245) 98.6 (52.5–271) 0.49 (0.27–1.75)
Pregnancy induced hypertension 8 (3.7%) 140 (110–151)a 85.3 (58.2–102) 0.64 (0.52–0.80)
Postmature delivery 14 (6.5%) 176 (138–333) 93.0 (59.9–194) 0.51 (0.26–0.84)
N.c.: not calculated.
ap = 0.071.
All other p-values > 0.1.
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Table  4
Linear regression analysis of birth weight, stratiﬁed for group, and adjusted for known confounders (cohort 1)
Covariate Unstandardized  (95% CI) Standardized  p Adjusted R2 (model)
Healthy controls (n = 118) ln [cortisone to cortisol ratio] 149 (−253–551) 0.06 0.5 0.362
Maternal height 12.5 (1.3–23.7) 0.17 0.029
Parity 294 (155–434) 0.32 <0.001
Infant sex 215 (79–350) 0.23 0.002
Gestational age at delivery 31.7 (21.8 41.6) 0.49 <0.001
Smoking during 1st trimester −69 (−610–471) −0.02 0.8
Gestational age at sampling −0.3 (−14.6–14.1) 0.00 1.0
Hour of day at sampling 0.0 (0.0–0.0) −0.02 0.8
Psychiatric morbidity (n = 92) ln [cortisone to cortisol ratio] 1162 (580–1744) 0.35 <0.001 0.333
Maternal height 20.2 (6.1–34.3) 0.25 0.006
Parity 161 (−19–341) 0.17 0.1
Infant sex −65 (−239–108) −0.07 0.5
Gestational age at delivery 19.4 (9.0–29.9) 0.34 <0.001
Smoking during 1st trimester −52 (−436–332) −0.02 0.8
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. Discussion
The major ﬁnding of the present study was that, contrary to our
ypothesis, third trimester maternal serum cortisol, cortisone, and
ortisone to cortisol ratio were similar between women with an
ntenatal depressive episode or other psychiatric morbidities and
ealthy controls. This ﬁnding is in line with a number of studies sug-
esting no difference in gestational cortisol levels between women
ith antenatal depression, anxiety, or stress and healthy controls
Hellgren et al., 2013; Iliadis et al., 2015)
A non-pregnant individual’s serum cortisone to cortisol ratio
as been proposed to be set by the total 11-HSD type 1 and type
 activity combined (Heilmann et al., 1999; Homma  et al., 2001)
nd a low cortisol to cortisone conversion has been found to be
ssociated with renal disease and hypertension (Homma  et al.,
001). We  found a mean cortisone to cortisol quotient that was
t least three times higher than what has been previously reported
n healthy non-pregnant controls (Homma  et al., 2001; Simunkova
t al., 2008). During pregnancy, the placental 11-HSD activity is
ikely to affect the maternal serum cortisone to cortisol ratio (Li
t al., 2013), but it is also possible that the 11-HSD2 activity in
he maternal kidney and 11-HSD1 activity in the maternal liver
nd adipose tissue are inﬂuenced by the endocrinology of preg-
ancy, as the enzymes may  be inhibited by progesterone and other
teroid hormones (Brown et al., 1996; Ricketts et al., 1998), as well
s induced by adrenocorticotropic hormone (ACTH) (Vogeser et al.,
001), all of which serum concentrations are high during late preg-
ancy.
The apparent bimodal distribution of cortisone to cortisol ratio
n our sample was an unexpected result which could not be
xplained by known demographic variables. Previously, normal
istribution of cortisone to cortisol ratio has been demonstrated
n healthy (non-pregnant) controls, and a bimodal distribu-
ion in hypertensive diabetes mellitus patients (Homma  et al.,
001). As the subpopulations in that study could be discerned
y liver and kidney function correlates, we  speculate that the
imodal distribution found in our comparatively healthy popula-
ion could represent different physiological strategies for handling
he increased demands on the liver and the kidneys during late
regnancy.
Of course, measurements of 11-HSD activity in placental tis-
ue or amniotic cortisol concentration are better indicators of fetal
ortisol exposure, which also take fetal cortisol production into
ccount. However, unlike placental and amniotic samples, mater-
al serum ratio is possible to obtain repeatedly during pregnancy
nd from a larger number of women, and could therefore prove to–97) −0.10 0.3
.3) 0.13 0.2
 0.07 0.4
be useful when targeting effects of maternal stress, or metabolic
state, on fetal development
We  found a weak but signiﬁcant positive association between
cortisone to cortisol ratio and infant birth weight. Goedhart et al.
have reported on the largest study to date on maternal serum cor-
tisol and birth weight (Goedhart et al., 2010). According to their
ﬁndings, the initial negative association between cortisol and birth
weight disappeared following adjustment for gestational age at
delivery, infant gender, ethnicity, maternal age, parity, BMI, and
smoking (Goedhart et al., 2010). Even though the negative impact
of fetal cortisol exposure on birth weight has been established in
experimental animal studies (Edwards et al., 1993), and corrob-
orated by human correlation studies (Aufdenblatten et al., 2009;
Stewart et al., 1995), the cortisol level in the maternal circulation
is an unreliable measure of fetal exposure, mainly due to the pla-
cental 11-HSD activity and fetal cortisol synthesis. Thus, the fact
that we could detect an association between the cortisone to corti-
sol ratio and birth weight with less than a tenth of the sample-size
of Goedhart et al. (2010), but not their initial correlation between
serum cortisol and birth weight, could support the notion that the
cortisone to cortisol ratio is a better indicator of the impact of
maternal cortisol on fetal growth.
In line with Goedhart et al., 2010 and our present results, Li et al.
(2012) did not ﬁnd birth weight to be associated with maternal
serum cortisol, sampled on the day of the delivery. However they
did observe a negative correlation between maternal cortisol and
ultrasound estimates of fetal head circumference, in the group of
women who were in labour at the time of sampling (Li et al., 2012).
In the present study, the association between the cortisone to
cortisol ratio and birth weight was  in signiﬁcant interaction with
maternal psychiatric status, as it was  not present in the healthy con-
trols, but was  driven by the women who  experienced psychiatric
morbidity during pregnancy. This ﬁnding is potentially explained
by previous ﬁndings of lower placental 11-HSD2 activity in
women with prenatal anxiety (O’Donnell et al., 2012). Considering
that there seems to be little correlation between placental 11-HSD
gene expression and the protein level, or the enzymatic activity
(Novembri et al., 2013; Wachter et al., 2009), the lack of group
difference in gene expression suggested by our results does not
exclude the possibility that the activities of placental 11-HSD is
affected by psychiatric morbidity (O’Donnell et al., 2012). There is
also some evidence that other parts of the glucocorticoid signaling
pathway in placenta are altered in women  with psychiatric morbid-
ity during pregnancy (Reynolds et al., 2015). Yet another possible
explanation to the interaction between psychiatric morbidity, cor-
tisone to cortisol ratio and birth weight is that the maternal level
of corticosteroid binding protein has been shown to be negatively
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orrelated with depressive symptoms (Pawluski et al., 2012), which
ould allow a larger portion of the total serum cortisol to cross the
lacenta in women with psychiatric morbidity.
However, with only the maternal serum ratio and placental 11-
SD expression levels at hand, we are not in a position to infer how
uch of the interindividual variation in cortisone to cortisol ratio
hat is dependent on placental 11-HSD activity. Clearly, the major
imitation of the study is that no functional measure of placental
1-HSD activity was obtained.
Measurements of 11-HSD activity in placental tissue or amni-
tic cortisol concentration are better indicators of fetal cortisol
xposure, which also take fetal cortisol production into account.
owever, unlike placental and amniotic samples, the maternal
erum ratio is possible to obtain repeatedly during pregnancy and
rom a larger number of women, and could therefore prove to be
seful when targeting effects of maternal stress, or metabolic state,
n fetal development.
Apart from a negative impact on birth weight, cortisol has also
een implied to shorten gestational length (Field et al., 2006). We
ound no association between cortisol (or cortisone to cortisol ratio)
nd gestational length in our population. It should be pointed out
hat the gestational length was restricted to 35 weeks or more by
nclusion criteria. Also, the gestational age at serum sampling was
ater in our study than in previous studies reporting an associa-
ion between cortisol and prematurity (Field et al., 2006). It has
een suggested that the impact of maternal glucocorticoids on fetal
rowth is less prominent in late gestation, when the fetus has its
wn cortisol production (Reynolds, 2013). To assess whether the
ortisone to cortisol ratio during late pregnancy is associated with
etal growth during the same time period, or if our ﬁnding is due
o relative intraindividual stability of the ratio over the course of
regnancy, a longitudinal design would be needed.
Contrary to the ﬁndings of O’Donnell et al. (2012), we noted no
ifference in placental expression levels of HSD11B1 or 2 accord-
ng to psychiatric status (cohort 2). In the smaller group of women
ho were part of cohort 1 and 2, we saw a weak negative correla-
ion between relative HSD11B2 expression and maternal cortisone
evels only. Except for the small sample size (n = 33), also the differ-
nce in time between the week 38 blood draw and the postpartum
lacental sampling makes this analysis highly exploratory. The
lacental HSD11B2 expression was less pronounced with increas-
ng gestational age at delivery, which is in line with an earlier
tudy pointing to a decrease in placental 11-HSD2 protein con-
ent and enzymatic activity toward term pregnancy (Murphy and
lifton, 2003). Lower placental HSD11B2 expression levels have also
een reported to be associated with spontaneous start of labour
Novembri et al., 2013). However, as mentioned before, their enzy-
atic activities are reported not to be in close correlation with the
ene expression, perhaps due to the rapid changes in expression
evels near term (Novembri et al., 2013; Wachter et al., 2009).
A major strength with our study is that the cortisol and cortisone
oncentrations were measured with tandem mass spectrometry, a
ethod which has been shown to be superior to an immunological
ssay for determining cortisol during late pregnancy (Jung et al.,
011).
One limitation to the study is that the number of participants
as too low to perform robust subgroup analyses of diagnose and
o-morbidity groups. Although our tentative subgroup analyses
id not indicate differences between women with depression or
nxiety and controls, the small size of the anxiety group and the
igh level of co-morbidity prevent us from drawing ﬁrm conclu-
ions. The observed lack of difference between healthy women  and
hose with psychiatric morbidity may  thus be an oversimpliﬁca-
ion that conceals different patterns of cortisol metabolism during
regnancy in different patient groups. Limitations also include the
igniﬁcant group differences in the demographic variables (gesta-crinology 69 (2016) 142–149
tional age at sampling, maternal age, and educational level). While
none of these variables were found to be signiﬁcantly associated
with the cortisone to cortisol ratio, it cannot be ruled out that
these differences may  have confounded an existing group differ-
ence. Also, as cortisol and cortisone are both subject to diurnal
rhythms as well as gestational age changes, the timing of sampling
is crucial for the interpretation of the results. The increasing serum
level of cortisol during pregnancy is accompanied by a blunted diur-
nal rhythm in cortisol concentration (Buss et al., 2009), but cortisol
and cortisone still display a diurnal rhythm at the very end of term
pregnancy (Seron-Ferre et al., 2001). Although the sampling in the
current study was not standardized to a single time-point, which
would be the ideal design, a majority of the samples were taken at
either 10:30 AM or 2:30 PM,  and the cortisone to cortisol ratio did
not differ signiﬁcantly between AM and PM samples. Furthermore,
ﬁnal regression analyses were adjusted for sampling time-point,
and gestational length.
In conclusion, we  found that late pregnancy maternal serum
cortisone, cortisol, and their ratio, did not differ between women
with psychiatric morbidity during pregnancy and healthy pregnant
controls. However, we found a positive correlation between mater-
nal cortisone to cortisol ratio and infant birth weight, which was
only present in the psychiatric morbidity group, suggesting that in
healthy women  the effects of a low cortisol to cortisone conver-
sion is buffered by a factor that women  with psychiatric morbidity
lack. Further studies assessing functional 11-HSD1 and 2 activ-
ity in women  with antenatal psychiatric morbidity are needed to
clarify this ﬁnding.
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